Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interventions for Cardiovascular Disease: "Real-World" Effectiveness of Combined Pharmacotherapy and Behavioural Counseling for Smoking Cessation
Brief Summary: Research Aims

The aims of this research study are:

1. To determine which of the following three smoking cessation medications is most effective in achieving cessation:

   * Nicotine Patch
   * Nicotine Patch + gum or inhaler
   * Varenicline (Champix;
2. To investigate how often participants experience neuropsychiatric symptoms over the course of their cessation attempt and to assess whether:

   * They occur more often when taking one medication versus another
   * They occur more often in those with or without psychiatric illnesses.

Hypotheses to be Tested

The hypotheses to be tested include the following:

1. The CO-confirmed continuous abstinence rate from 5 weeks to 52 weeks following a target quit date will be significantly higher in smokers receiving long-term transdermal NRT in combination with other NRT products or those receiving varenicline compared to those receiving transdermal NRT alone.
2. Some participants will experience neuropsychiatric symptoms during their cessation attempt, and those in the varenicline group will experience a greater incidence of neuropsychiatric symptoms than those in the groups receiving transdermal NRT alone or in combination with other NRT products. Patients with psychiatric illnesses will report higher levels of withdrawal symptoms than those without psychiatric illnesses.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: Varenicline + Patch Standard Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patch, Other: Placebo Patch, Other: Placebo Pill | Arm Label: Varenicline Only Standard Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Other: Placebo Patch, Other: Placebo Pill | Arm Label: Varenicline + Patch Extended Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patch | Arm Label: Varenicline Only Extended Duration; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Other: Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Patch Extended Duration, Varenicline + Patch Standard Duration, Varenicline Only Extended Duration, Varenicline Only Standard Duration | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Varenicline + Patch Extended Duration, Varenicline + Patch Standard Duration | Intervention Type: OTHER; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Patch Standard Duration, Varenicline Only Extended Duration, Varenicline Only Standard Duration | Intervention Type: OTHER; Name: Placebo Pill; Assigned to Arm(s): Varenicline + Patch Standard Duration, Varenicline Only Standard Duration
C: Arm Label: Champix; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: Long & Combination patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch combined with gum or inhaler | Arm Label: Standard patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix | Intervention Type: DRUG; Name: Transdermal Nicoderm patch combined with gum or inhaler; Assigned to Arm(s): Long & Combination patch treatment | Intervention Type: DRUG; Name: Transdermal Nicoderm patch; Assigned to Arm(s): Standard patch treatment
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: C